Introduction
============

Cardiovascular diseases (CVDs, including coronary artery disease, stroke, and peripheral vascular disease) are the leading causes of morbidity and mortality in Western and developed countries.[@b1-vhrm-8-455]--[@b3-vhrm-8-455] Almost half the disease burden in developing countries is already due to noncommunicable diseases, including CVD.[@b3-vhrm-8-455]

In sub-Saharan Africa (SSA), the INTERHEART Africa Study reports that traditional CVD risk factors (smoking, diabetes mellitus, hypertension, abdominal obesity, and ratio of apolipoprotein B to apolipoprotein A-1) account for almost 90% of myocardial infarction,[@b4-vhrm-8-455] which is consistent with the overall INTERHEART study.[@b5-vhrm-8-455] This has fostered the search for additional, nontraditional risk factors or risk factor equivalents for CVD among black Africans with low prevalence of coronary artery disease.[@b6-vhrm-8-455]

Furthermore, the absence of traditional and known risk factors does not totally protect Central Africans from CVD.[@b7-vhrm-8-455],[@b8-vhrm-8-455] Consistent with many studies from the literature,[@b9-vhrm-8-455]--[@b12-vhrm-8-455] we reported that *Helicobacter pylori* infection, one of the new CVD risk factors, has been epidemiologically linked to metabolic syndrome and established CVD.[@b13-vhrm-8-455],[@b14-vhrm-8-455] However, the predictive role of *H. pylori* infection in CVD is still a matter of debate,[@b15-vhrm-8-455] and that of the interaction between infection and sex is unknown in our setting.

In Central Africans with low serum triglycerides, *H. pylori* seropositivity per se might generate CVD both in general and particularly in men with *H. pylori* infection.[@b13-vhrm-8-455] A causal association between *H. pylori* infection and CVD would be of major health importance in SSA countries, such as Democratic Republic of the Congo, because the infection can be evaluated and eradicated with first-, second-, and third-line eradication therapy (proton-pump inhibitors + amoxicillin + clarithromycin, and others),[@b16-vhrm-8-455] which showed prevention of cardiometabolic risk in our previous study[@b13-vhrm-8-455] and in Italy.[@b17-vhrm-8-455]

The aim of our study, therefore, was to evaluate potential cross-sectional and prospective associations between *H. pylori* seropositivity and CVD risk factors in a screening population, as well as to investigate a prospective association between sex and CVD among participants with *H. pylori* seropositivity.

Methods
=======

After the study design ([Figure 1](#f1-vhrm-8-455){ref-type="fig"}) was approved by the ethical committee of the Lomo Medical Center, 205 patients (128 with *H. pylori* infection \[HP-seropositive\], 77 without \[HP-seronegative\]) had a baseline assessment for other potential CVD risk factors in 1999 and had monthly follow-up at the Lomo Medical Center for 10 years until 2008. A questionnaire, electrocardiogram (ECG), enzymes, neurological exam, and carotid ultrasonography were completed at the baseline assessment, at the onset of any acute CVD event, and at the final evaluation (mean time between baseline and conclusion of follow-up = 9.6 ± 0.8 years).

At the baseline examination, participants were not suffering from CVD, gastric ulcer, chronic infection, or cancer. HP-seropositives and HP-seronegatives were matched for the following CVD risk factors: sex, age, smoking, alcohol intake, body mass index (BMI), waist circumference, heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), and leukocytes. Further, serum total cholesterol, high-density lipoprotein cholesterol (HDL-cholesterol), low-density lipoprotein cholesterol (LDL-cholesterol), triglycerides, fibrinogen, intima-media thickness (IMT), arterial hypertension, diabetes mellitus, socioeconomic status, and residence were assessed on a monthly basis for the outcomes of peripheral vascular disease, angina pectoris, myocardial infarction, and stroke within the Division of Cardiology at the Lomo Medical Center, Kinshasa, Limete, Democratic Republic of the Congo.

A structured and standardized questionnaire consisted of demographic information; past, current and future medical history; and a systematic review of symptoms, including acute chest pain and CVD.

All participants underwent ECG[@b18-vhrm-8-455] and physical measurements[@b19-vhrm-8-455] by trained medical doctors and registered nurses.

Outpatients wore light clothes during measurements of body weight to the nearest 100 g using calibrated scales, height with bare feet to the nearest mm, waist circumference in duplicate at the level midway between the lowest rib margin and the iliac crest, and hip circumference at the widest trochanters to the nearest mm; the mean values of circumferences were used in analysis. BMI was calculated as weight (kg) divided by height squared (m^2^).

Blood pressure (BP) and heart rate were recorded using an Omron HEM 705 electronic BP manometer (Omron Life Science Co, Ltd, Tokyo, Japan) after the patient rested for 5 minutes. BP and heart rate were taken three times on the left arm in the supine position at the level of the heart, by the same trained physician (BLM), following the World Health Organization (WHO) guidelines.[@b20-vhrm-8-455]

Laboratory analyses
-------------------

Blood samples were drawn between 08:00 and 10:00 after a 12-hour fast and 30 minutes of rest. All laboratory specimens were analyzed by the same technician from Lomo Medical Center. Blood was assayed for standard leukocyte count, glucose, fibrinogen, and *H. pylori* seropositivity. Fibrinogenemia was measured using the electromagnetic water-bath method and bioMérieux Fibriquick kit (bioMérieux, Marcy l'Etoile, France), based on the Clauss method (normal range = 1.8--4 g/L). FPG was determined using the glucose oxidase method (Boehringer, Mannheim, Germany).

Immunoglobulin G (IgG) antibodies to *H. pylori* (anti-HP Ab) were measured by a commercial enzyme-linked immunosorbent assay (Pyloriset^®^ EIA-G; Orion Diagnostica, Espoo, Finland) by linear regression analysis. The sensitivity and specificity of the assay were higher than 95%. The range of serum levels of anti-HP Ab was between 100 U and 12,800 U.

Carotid ultrasonography
-----------------------

A single certified sonographer (BLM) performed the carotid B-mode ultrasound imaging using a Biosound Phase Two ultrasonography device equipped with a 7.5 Mhz annular array probe (Biosound Inc, Indianapolis, IN). This B-mode ultrasound imaging protocol was designed to ensure a valid and reliable identification of arterial carotid references and the definition of near and far wall interfaces. Because the bifurcations and not the common carotids are a preferential site for atherosclerosis,[@b20-vhrm-8-455] we measured IMT at both these sites.[@b21-vhrm-8-455] The key anatomical features defining these segments were the proximal origin of the bulb and the tip of the flow divider that separated internal from external carotid arteries. In longitudinal artery images, two main interfaces, corresponding to specific anatomical boundaries, were associated to the scanning and reading protocol described by Bond et al.[@b22-vhrm-8-455] Scans from all outpatients were read by the same reader without knowledge of *H. pylori* seropositivity. A random sample of outpatients (10%) was selected for a repeat examination to determine intravariability ( methodological reproducibility). Mean maximum IMT was calculated as the mean of the maximum IMT detected in the far walls of up to six carotid artery segments. The mean of the maximum IMT of the common and bifurcation far walls and the single maximum IMT were also calculated. Intrareader Pearson's correlation coefficients for these three measurements were 0.871, 0.908, and 0.746, respectively.

Definitions
-----------

Dyslipidemia (elevated total cholesterol and low HDL-cholesterol) and diabetes mellitus were defined from medical records.

*H. pylori* infection was defined as IgG anti-HP Ab \> 300 U. Hypertension was defined both by medical history and treatment of arterial hypertension and by criteria for arterial hypertension, such as SBP \> 140 mmHg or DBP \> 90 mmHg, according to WHO/International Society of Hypertension guidelines.[@b20-vhrm-8-455] BMI ≥ 25 kg/m^2^ was a criterion for overweight/obesity.[@b23-vhrm-8-455] Carotid plaques were characterized by carotid artery thickening \> 1.3 mm.[@b24-vhrm-8-455]

Statistical analysis
--------------------

Data were expressed as mean ± standard deviation (SD) or percentages. The significance of differences was determined using the unpaired Student's *t*-test when comparing baseline continuous data. The Chi-square test was used for comparing percentages of categorical data. IgG anti-HP Ab, hypertension, diabetes, obesity, lipid profile, smoking, alcohol intake, age, SBP, DBP, leukocyte count, sex, FPG, IMT, and fibrinogen were incorporated as explanatory variables in the logistic regression. Therefore, after adjusting for confounders, the relationship of angina pectoris, acute myocardial infarction, acute stroke, and carotid plaque as dependent variables was analyzed separately in the global study population and in the patients with *H. pylori* infection. The required significance level for tests was set at a *P* value \< 0.05. Statistical analysis was performed using the SPSS package for Windows (version 18; SPSS Inc, Chicago, IL).[@b25-vhrm-8-455]

Results
=======

A total of 205 black urban Congolese individuals were enrolled in this study (response rate of 85.4% out of 240 people included). Among 35 patients excluded at the final examination, 20 had died, 10 were lost to follow-up and five were excluded for medication intake. They were divided into two groups according to *H. pylori* seropositivity, classified as either HP-seropositive (n = 128) or HP-seronegative (n = 77).

At baseline examination, there was a significant association among elevated values of carotid artery IMT, blood fibrinogen, total cholesterol, FPG, and uric acid; lower levels of HDL-cholesterol; and *H. pylori* seropositivity ([Table 1](#t1-vhrm-8-455){ref-type="table"}). As expected, the mean values of age, BMI, waist circumference, heart rate, SBP, DBP, and leukocyte count in HP-seropositives were similar (*P* \> 0.05) to those in HP-seronegatives. The mean values of triglycerides and LDL-cholesterol were similarly low in the two groups.

At baseline examination, the HP-seropositive group and the HP-seronegative group had similar rates of cigarette smoking, alcohol intake, diabetes mellitus, and arterial hypertension ([Table 2](#t2-vhrm-8-455){ref-type="table"}). When sex was taken into account at the baseline assessment, men had significantly higher levels of IgG anti-HP Ab, waist circumference, SBP, DBP, uric acid, and total cholesterol than women ([Table 3](#t3-vhrm-8-455){ref-type="table"}). However, age, BMI, FPG, HDL-cholesterol, fibrinogen, and LDL-cholesterol did not vary (*P* \> 0.05) between males and females.

In the HP-seropositive group at the baseline check-up, there was a significant association among increases in rates of elevated fibrinogen, diabetes mellitus, low HDL-cholesterol, elevated total cholesterol, arterial hypertension, and severity of HP-seropositivity by comparing quartile 4 for IgG anti-HP Ab with quartile 1 ([Table 4](#t4-vhrm-8-455){ref-type="table"}).

Final evaluation for all participants
-------------------------------------

At the end of the follow-up, 60 participants (29.3%) had developed carotid plaques (35.2%, n = 45 in HP-seropositives vs 19.5%, n = 15 in HP-seronegatives; *P* \< 0.0001), and 36 participants (17.6%) had experienced acute stroke (23.4%, n = 30 in HP-seropositives vs 7.8%, n = 6 in HP-seronegatives; *P* \< 0.0001).

After adjusting for traditional risk factors, only HP-seropositivity was identified as a significant and independent predictor of incident carotid plaque (multivariate-adjusted odds ratio \[OR\] = 2.3, 95% confidence interval \[CI\]: 1.2--7.2; *P* \< 0.0001) in logistic regression model 1, as well as a significant and independent predictor of incident acute stroke (multivariate-adjusted OR = 3.6, 95% CI: 1.4--8.2; *P* \< 0.0001) in logistic regression model 2.

Final evaluation for the HP-seropositive group
----------------------------------------------

Among HP-seropositives, the incident CVD events were angina pectoris, estimated 21.9% (n = 28: 32.3%, n = 20 in men vs 12.1%, n = 8 in women; *P* \< 0.0001); acute myocardial infarction, estimated 25% (n = 32: 41.9%, n = 26 in men vs 9.1%, n = 6 in women; *P* \< 0.0001); and acute stroke, estimated 14.1% (n = 18: 21%, n = 13 in men vs 7.6%, n = 5 in women; *P* \< 0.0001).

After adjusting for traditional risk factors, male HP-seropositives developed a higher risk of incidence of angina pectoris (multivariate-adjusted OR = 3.5, 95% CI: 1.6--16; *P* \< 0.0001), acute stroke (multivariate-adjusted OR = 3.2, 95% CI: 1.4--28; *P* \< 0.0001), and acute myocardial infarction (multivariate-adjusted OR = 7.2, 95% CI: 3.1--18; *P* \< 0.0001), respectively, in logistic regression models 3, 4, and 5.

Discussion
==========

To the best of our knowledge, this is the first study clarifying the importance of HP-seropositivity to CVD risk in asymptomatic Central Africans. In HP-seropositives, the association between male sex and CVD was also shown in this study.

The present data on CVD and its traditional risk factors confirm the rapidly changing epidemiologic and clinical spectrum of noncommunicable diseases in SSA in general and in urban areas in particular.[@b4-vhrm-8-455]--[@b8-vhrm-8-455],[@b26-vhrm-8-455],[@b27-vhrm-8-455]

The present findings demonstrated that *H. pylori* infection is significantly associated with male sex; with high levels of fibrinogen, total cholesterol, uric acid, and FPG; and with low HDL-cholesterol, as reported by other studies.[@b12-vhrm-8-455]--[@b14-vhrm-8-455],[@b17-vhrm-8-455] However, this study did not confirm significant associations between high LDL-cholesterol and *H. pylori* infection[@b12-vhrm-8-455] or between triglycerides and *H. pylori* infection.[@b11-vhrm-8-455] Akbas et al reported that there is no significant difference in serum HDL-cholesterol, LDL-cholesterol, or total cholesterol between HP-seropositives and HP-seronegatives.[@b11-vhrm-8-455]

In all participants, seropositivity for IgG anti-HP Ab was significantly related to incident carotid plaques and acute stroke, but neither to angina pectoris nor to acute myocardial infarction. The group's young average age and a lipid profile within the normal range may explain the absence of coronary vessel dysfunction.[@b28-vhrm-8-455] *H. pylori* infection could be linked to the early stages of coronary atherosclerosis rather than advanced coronary atherosclerosis.[@b29-vhrm-8-455] Stroke is commoner than coronary heart disease in Africans with severe and uncontrolled hypertension.[@b7-vhrm-8-455] Progression of carotid lesions already associated with *H. pylori* infection may explain the onset of carotid plaques and stroke[@b30-vhrm-8-455] in this screening population. However, carotid atherosclerosis is not related to *H. pylori* infection in the United Kingdom,[@b31-vhrm-8-455] whereas HP-seropositivity is associated with carotid plaques and cerebrovascular and cardiovascular events in Italy.[@b32-vhrm-8-455]

Our data clearly demonstrate that severity of *H. pylori* infection was significantly associated with the most important traditional risk factors for CVD, such as diabetes mellitus, arterial hypertension, high levels of serum fibrinogen and total cholesterol, and low HDL-cholesterol. In these HP-seropositives, male sex was the only independent predictor of both cerebrovascular and coronary heart diseases. *H. pylori* infection showed an extremely broad spectrum of disease outcomes. These findings lend support to the notion that chronic *H. pylori* infection with exacerbation of inflammation (elevated fibrinogen), male sex (smoking) and dyslipidemia may contribute to early onset of atherosclerosis[@b33-vhrm-8-455],[@b34-vhrm-8-455] in those Africans facing demographic transition. Severity of HP-seropositivity in this infected group may reflect virulent strains bearing the cytotoxin-associated protein (CagA), with changes in inflammatory markers and higher risk of myocardial infarction.[@b10-vhrm-8-455],[@b35-vhrm-8-455]

Clinical implications
=====================

Our results will have clinical and public health implications for the prevention, detection and eradication of *H. pylori* infection. These strategies may reduce the burden of CVD and its associated high costs, morbidity and mortality.

Considerable evidence suggests that ultrasonic measurements of early atherosclerosis are clinically significant. It remains unclear what causes the chronic inflammatory state within carotid plaque. Action of *H. pylori* bacteria either directly on vascular cells or via the indirect effects of cytokines and acute-phase proteins at nonvascular sites may be incriminated in this accelerated atherosclerosis.[@b35-vhrm-8-455],[@b36-vhrm-8-455]

Study limitations
=================

Dependence on only serological evidence for presence of *H. pylori* infection; small sample size; and lack of markers, such as C-reactive protein, PON-1, and Cag, could be the limitations of this study. Its strength, however, is its prospective design with suitable adjustments for confounding factors.

Conclusion
==========

CVD and its traditional risk factors are emerging as public problems among Central Africans.

In general, *H. pylori* infection may contribute to high risk of carotid plaque and stroke by its relationship with traditional CVD risk factors.

In the HP-seropositive group, very high levels of IgG anti-HP Ab are significantly associated with traditional CVD risk factors, while men are at higher risk of angina pectoris, stroke, and myocardial infarction than women.
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###### 

Comparison of studied parameters in participants with and without *H. pylori* infection at the baseline examination

  Variables of interest            With *H. pylori* infection (n = 128)   Without *H. pylori* infection (n = 77)   *P*-value
  -------------------------------- -------------------------------------- ---------------------------------------- -----------
  Age (years)                      53.4 ± 12.9                            52.5 ± 16.6                              NS
  BMI (kg/m^2^)                    26.4 ± 4.9                             24.9 ± 5.4                               NS
  Waist circumference (cm)         101.9 ± 11.4                           98.7 ± 16.1                              NS
  Heart rate/minute                78.3 ± 14.3                            76.9 ± 14.6                              NS
  SBP (mmHg)                       159.9 ± 36.8                           153.4 ± 34.4                             NS
  DBP (mmHg)                       92 ± 20.9                              90.8 ± 19.5                              NS
  Leukocytes/mm^3^                 6.3 × 10^3^ ± 2.4 × 10^3^              5.9 × 10^3^ ± 2.5 × 10^3^                NS
  Fibrinogen (mg/dL)               471.5 ± 23.6                           297.2 ± 14.7                             \<0.0001
  IMT, carotid artery (mm)         0.8 ± 0.1                              0.6 ±                                    \<0.0001
  Total cholesterol (mg/dL)        216.4 ± 43.6                           173.3 ± 38.9                             \<0.01
  Triglycerides (mg/dL)            100.5 ± 32.1                           98.4 ± 34.4                              NS
  LDL-cholesterol (mg/dL)          102.3 ± 8.5                            101.1 ± 15.1                             NS
  HDL-cholesterol (mg/dL)          56.8 ± 21.2                            96.4 ± 21.3                              \<0.01
  Fasting plasma glucose (mg/dL)   106.6 ± 41.2                           84 ± 15                                  \<0.01
  Uric acid (mg/dL)                15.2 ± 1.7                             5.1 ± 2                                  \<0.0001

**Abbreviations:** *H. pylori*, *Helicobacter pylori*; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; IMT, intima media thickness; LDL, low-density lipoprotein; HDL, high-density lipoprotein, NS, nonsignificant.

###### 

Traditional risk factors in all participants according to *H. pylori* serologic status

  ---------------------------------------------------------------------------------------------------------------------
  Variables of interest   With *H. pylori* infection (n = 128)\   Without *H. pylori* infection (n = 77)\   *P*-value
                          n (%)                                   n (%)                                     
  ----------------------- --------------------------------------- ----------------------------------------- -----------
  Cigarette smoking       21 (16.6)                               12 (15.6)                                 NS

  Alcohol intake          19 (14.9)                               11 (14.3)                                 NS

  Diabetes mellitus       13 (10.2)                               8 (10.4)                                  NS

  Arterial hypertension   30 (23.4)                               18 (23.3)                                 NS
  ---------------------------------------------------------------------------------------------------------------------

**Abbreviations:** NS, nonsignificant; *H. pylori*, *Helicobacter pylori.*

###### 

Mean values of continuous data for known indicators of CVD risk according to sex

  Variables of interest                    Men mean ± SD   Women mean ± SD   *P*-value
  ---------------------------------------- --------------- ----------------- -----------
  IgG antibodies against *H. pylori* (U)   2475 ± 362      1246 ± 126        \<0.0001
  Age (years)                              52 ± 12         53 ± 15           NS
  BMI (kg/m^2^)                            27.4 ± 5.1      26.4 ± 5.1        NS
  Waist circumference (cm)                 99.6 ± 12.8     90.3 ± 15.1       \<0.05
  SBP (mmHg)                               169.2 ± 30.1    147.7 ± 39.9      \<0.01
  DBP (mmHg)                               98.8 ± 18.6     81.9 ± 21.2       \<0.0001
  Uric acid (mg/dL)                        11.6 ± 3.4      5.7 ± 1.9         \<0.01
  Fasting plasma glucose (mg/dL)           111 ± 42        99.4 ± 35.2       NS
  Total cholesterol (mg/dL)                218.7 ± 83.2    182.3 ± 63.6      \<0.01
  HDL-cholesterol (mg/dL)                  62.2 ± 26.8     60.8 ± 32.3       NS
  Fibrinogen (mg/dL)                       477.6 ± 22.6    466.3 ± 25.4      NS
  LDL-cholesterol (mg/dL)                  101 ± 28        100.5 ± 29.6      NS

**Abbreviations:** CVD, cardiovascular disease; SD, standard deviation; IgG, immunoglobulin G; *H. pylori*, *Helicobacter pylori*; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

###### 

Traditional risk factors by quartiles for IgG anti-HP Ab in individuals seropositive for *H. pylori*

  --------------------------------------------------------------------
  Variables of interest        Quartile 4\   Quartile 1\   *P*-value
                               n = 32        n = 32        
  ---------------------------- ------------- ------------- -----------
  Elevated fibrinogen          9 (28.1)      3 (10)        \<0.001

  Diabetes mellitus            7 (21.9)      2 (6.3)       \<0.001

  Low HDL-cholesterol          9 (28.1)      1 (3.1)       \<0.0001

  Elevated total cholesterol   16 (50)       9 (28.1)      \<0.0001

  Arterial hypertension        26 (81.3)     19 (59.4)     \<0.001
  --------------------------------------------------------------------

**Abbreviations:** IgG anti-HP Ab, immunoglobulin G antibodies against *H. pylori*, *Helicobacter pylori*; HDL, high-density lipoprotein.
